Showing 1 - 10 of 16
We examine how and why pre-existing vertical scope may cause differences in product market exit rates after sudden and exogenous decreases in demand. Our empirical context is the U.S. medical diagnostic imaging industry (2004-2009), wherein a major Medicare reform created a derived demand shock...
Persistent link: https://www.econbiz.de/10013491822
Persistent link: https://www.econbiz.de/10014342084
Persistent link: https://www.econbiz.de/10009407128
Persistent link: https://www.econbiz.de/10009671834
Pandemics and epidemics pose risks to lives, societies, and economies, and their frequency is expected to increase as rising trade and increased human interaction with animals leads to the emergence of new diseases. The COVID-19 pandemic teaches us that we can and must be better prepared, with...
Persistent link: https://www.econbiz.de/10014082953
How can the world reach herd immunity against COVID-19 before the second anniversary of the pandemic, or March 2022? A study of vaccine demand and supply answers this question. A target of vaccinating 60 percent of the population in each country by March 2022 is likely sufficient to achieve...
Persistent link: https://www.econbiz.de/10013232358
To examine the drivers of innovation, this paper studies the global R&D effort to fight the deadliest diseases and presents four results. We find: (1) global pharmaceutical R&D activity - measured by clinical trials - typically follows the 'law of diminishing efforts': i.e. the elasticity of R&D...
Persistent link: https://www.econbiz.de/10012430944
Urgent steps are needed to arrest the rising human toll and economic strain from the COVID-19 pandemic that are exacerbating already-diverging recoveries. Pandemic policy is also economic policy as there is no durable end to the economic crisis without an end to the health crisis. Building on...
Persistent link: https://www.econbiz.de/10012522396
To examine the drivers of innovation, this paper studies the global R and D effort to fight the deadliest diseases and presents four results. We find: (1) global pharmaceutical R and D activity-measured by clinical trials-typically follows the 'law of diminishing effort': id est the elasticity...
Persistent link: https://www.econbiz.de/10012518690
The experience of the Great Recession and its aftermath revealed that a lower bound on interest rates can be a serious obstacle for fighting recessions. However, the zero lower bound is not a law of nature; it is a policy choice. The central message of this paper is that with readily available...
Persistent link: https://www.econbiz.de/10012019855